Skip to main content

FDA green lights Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Psychedelic Drug Trial for Treating Fibromyalgia, After Completing IND Process

  • Pharmaceutical company Tryp Therapeutics is advancing research into the ability to treat unmet medical needs by using synthetic psychedelic drug candidates generally regarded as illegal and of no practical value under federal drug standards
  • The company is demonstrating its faith in the potential of psychedelic medicine by advancing its proprietary TRP-8802 psilocybin candidate toward Phase 2a drug trials through the FDA’s Investigational New Drug process
  • The FDA has notified the company that its review of the IND for using TRP-8802 to treat fibromyalgia is complete and a trial planned in conjunction with the University of Michigan may proceed to patient enrollment
  • Tryp is also preparing Phase 2a drug trials for testing TRP-8802 in treating eating disorders at the University of Florida, and for treating phantom limb pain and complex regional pain syndrome

Psychedelic drug medical research firm Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF) has received final U.S. Food and Drug Administration (“FDA”) approval to get under way with its planned clinical study of its synthetic psilocybin drug candidate TRP-8802 for treating fibromyalgia.

“The upcoming Phase 2a study with the University of Michigan for fibromyalgia represents a significant milestone for Tryp’s clinical programs,” Tryp Chairman and CEO Greg McKee stated in the…

Read More>>

NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at

About PsychedelicNewsWire

PsychedelicNewsWire (PNW) is a specialized content distribution company that (1) aggregates and distributes news and information on the latest developments in all aspects and advances of psychedelics and their use, (2) creates PsychedelicNewsBreaks designed to quickly update investors on important industry news, (3) leverages a team of expert editors to enhance press releases for maximum impact, (4) assists companies with the management and optimization of social media across a range of platforms, and (5) delivers unparalleled corporate communication solutions. PNW stays abreast of the latest information and has established a reputation as the go to source for coverage of psychedelics, therapeutics and emerging market opportunities. Our team of seasoned journalists has a proven track record of helping both public and private companies gain traction with a wide audience of investors, consumers, media outlets and the general public by leveraging our expansive dissemination network of more than 5,000 key syndication outlets. PNW is committed to delivering improved visibility and brand recognition to companies operating in the emerging markets of psychedelics.

To receive instant SMS alerts, text “Groovy” to 21000 (U.S. Mobile Phones Only)

For more information please visit

Please see full terms of use and disclaimers on the PsychedelicNewsWire website applicable to all content provided by PNW, wherever published or re-published:

Do you have questions or are you interested in working with PNW? Ask our Editor

PsychedelicNewsWire (PNW)
San Francisco, California
415.949.5050 Office

PsychedelicNewsWire is part of the InvestorBrandNetwork.

Data & News supplied by
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.